Recombinant Technologies

Revolutionary Alzheimer's Treatment

Recombinant Technologies

Revolutionary Alzheimer's Treatment

Cheshire, CT
Health Tech
Diversity Ownership
Recombinant Technologies is developing a revolutionary treatment for Alzheimer's Disease. By designing an injection of a molecule treatment to reduce the plaque buildup that causes dementia, we have successfully improved memory in mice and are ready to move toward human trials.

$66,163

raised
123
Investors
$35M
Valuation
$1.00
Price per Share
$200.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
Reg CF
Offering

$66,163

raised
123
Investors
$35M
Valuation
$1.00
Price per Share
$200.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
Reg CF
Offering

Rewards

Get rewarded for investing more into Recombinant Technologies:

$200+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$500+
Investment
Tier 1
Invest $500 and receive 2% bonus shares.
$1,000+
Investment
Tier 2
Invest $1,000 and receive 5% bonus shares.
$2,500+
Investment
Tier 3
Invest $2,500 and receive 7% bonus shares.
$5,000+
Investment
Tier 4
Invest $5,000 and receive 10% bonus shares.
$10,000+
Investment
Tier 5
Invest $10,000 and receive 15% bonus shares.

Reasons to Invest

There are an estimated 5,500,000 people in the U.S. who have Alzheimer’s disease, and we have developed an innovative treatment that addresses the cause of the disease rather than the symptoms. By this treatment strategy, we are addressing a significant unmet medical need and opportunity.
Our patented technology was developed over a decade with the support of $4.5 million in grants and has successfully improved memory in mice in our proof of concept trials.
Our team is comprised of top experts in their fields, including our founder who trained at Yale School of Medicine for about a decade prior to founding this company.



Treating the Root Cause of Alzheimer’s Disease


We have developed a patented molecule (AmyTrap) with demonstrated success in animal-model proof of concept studies to remove amyloid-beta, which is the physiological cause behind the plaque buildup in the brain associated with Alzheimer's Disease. 



Incorporating that same molecule, we designed and developed two types of extracorporeal devices, called AmyTrappers, for treatments. These proposed innovative devices trap amyloid from circulation (just like dialysis to remove urea in patients with kidney failure) which may lead to achieving a novel treatment strategy that improves the lives of patients with AD.


We are excited about the promising results AmyTrapper has shown up to this point, and are now ready to bring our technology to the next level through new research that will result in the initiation of human trials.

The problem


Current Alzheimer’s Disease Treatments Fall Short


Alzheimer’s Disease (AD) is a common disease leading to dementia affecting millions of people worldwide.  


One of the many targets in treatment for AD is amyloid-beta plaque buildup. However, currently there are no treatments that address amyloid-beta as the underlying pathophysiology behind Alzheimer’s. Instead, most current drugs work to alleviate symptoms or marginally slow disease progression. Recently,  Biogen’s Aduhelm(Adecanumab) was accepted by the FDA  as the first treatment that targets reduction of amyloid- beta plaque in the brain. This underscores the significance of amyloid- beta plaque removal strategies as a key against Alzheimer’s . 


The solution


AmyTrap Treats the Cause, Not Just the Symptoms


Our prototype, AmyTrap, is designed to reduce disease-causing amyloid-beta plaque burden, improving memory by addressing the physiological cause behind Alzheimer’s Disease.


*Image is a computer-generated demo version. Product is still currently under development.


Use of the technology will slow disease progression in individuals at high risk of developing Alzheimer’s disease, increasing the duration of their independence and lessening third-party payor outlay for symptomatic treatments and caregiving.

The market


Meeting a Growing Need in Alzheimer’s Treatment


We estimate the total market size to be approximately $570,000,000 at the growth rate of 17.5% in 2018. 5,500,000 people in the U.S. have Alzheimer’s disease, and 5% of these patients have early-onset Alzheimer’s disease due to genetic or other factors.


Source

The niche therefore consists of 285,000 patients, and at $2000 per year in treatment, that amounts to a $570,000,000 total potential market. We believe that Amytrapper will be one of the few devices in the immediate future to address this unmet medical need by treating this subset population. 

our traction


Promising Early Results and Patented Technology


We have established proof of concept through our animal model, where we saw improved memory and behavior in model mice after treatment. In addition, toxicity and safety assessments in rats and dogs have been completed. Amytrap, the underlying molecule, was found to be safe and non toxic. Further, Amytrapper animal testing is in progress. 



We have achieved Intellectual Property protection in the form of a patent issued by USPTO which has been issued to Recombinant Technologies LLC. We have also won multiple small business innovation grants from the National institutes of Health through a rigorous peer-review process.

what we do


Clearing Plaque Buildup to Improve Memory

AmyTrap is a patented molecule composed of polymer-bound short peptides with the capacity to capture beta-amyloid (Aβ) peptide. Amytrap binds and sequesters Aβ from the circulation, leading to the depletion of amyloid plaques from the brain in model mice. 



Our preliminary studies in animal models suggest that AmyTrap does not enter the brain. Undetectable levels of AmyTrap and reduction of the Aβ burden in the brain suggest that the AmyTrap possibly exerts its therapeutic activity by acting as a peripheral sink for circulatory Aβ. Based on these observations it has been hypothesized that Aβ exists in equilibrium between the brain and in circulation. Sequestration of the circulatory Aβ in the periphery creates an imbalance in this equilibrium driving efflux of Aβ from the brain into the circulation.


The business model


Working with Established Partners to Reach High-Risk Patients


Currently, we are pre-commercialization and looking to perform additional research to perfect our product. 


When we are ready for commercialization, our strategy will initially be aimed at therapy towards individuals at highest risk, in particular those with familial or genetic predisposition for onset of Alzheimer’s disease. We plan to partner with established organizations with a substantial footprint in the marketplace to implement our treatment. 


*Likely to increase overtime


We estimate the cost per treatment to be approximately $500. Four treatments per patient per year are proposed, which would generate revenue of $2000 per patient per year. We are the only player in this market as of now.



How we are different


Our Technology Stops Alzheimer’s at the Source


According to our research, AmyTrapper devices are among the first of their kind in their focus on the depletion of beta amyloid from the brain prior to memory deterioration. Rather than functioning as an anti-beta amyloid antibody, our treatment specifically binds to the critical region of beta amyloid necessary for aggregation.





We expect this breakthrough to significantly improve the living condition of people with Alzheimer’s Disease, especially with its focus on early intervention. 

the vision


Developing a Life-Changing Treatment


We see our technology as an opportunity to improve the lives of the many patients suffering from Alzheimer’s Disease and related dementia. 


Our goal is to complete the studies to get FDA approval of the device within two to three years. Upon this milestone, we plan to exit by outright sale or license the technology out on a milestone and royalty reimbursement model.



our leadership


Experts in Science, Medicine, and Finance


Dr. Pazhani Sundaram, the Founder-President has wide experience in research and development. He was trained at Yale School of Medicine for about a decade prior to founding this company. He has successfully performed a clinical trial on a cholesterol-lowering Indian herbal medicine and commercialized it in the Indian pharmaceutical market.



Our team represents decades of experience across scientific research, biopharmaceuticals, and finance. We believe strongly that this technology will fill an unmet medical need and change many people’s lives for the better. 

why invest


A Unique Treatment for a Better World


In 2021, treatment of patients with Alzhemier’s Disease and dementia will cost the nation $355 billion, and this cost is likely to increase to $1.1 trillion by 2050. We need to change the way we are approaching the problem. 



Through our technological innovation, we believe we can stop beta amyloid plaque build-ups before they happen in the brain, rather than simply treating the symptoms. Our promising proof of concept trial results alongside our patented technology have us well prepared to move into the next phase of trials. 


In the Press

'Amytrapper', a Novel Immobilized Sepharose API Matrix, Removes Amyloid-β from Circulation in vitro

Recombinant Technologies LLC (RTL) has developed and studied its proprietary Amytrap peptide to remove Aβ from circulation which in turn depletes brain Aβ in a clinically relevant mouse model of AD. The results provide a proof of concept for our proposed prototype design for an Amytrapper device.

Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer's Disease

Efficacy evaluations were performed on model mice. Pharmacokinetics and safety toxicology were assessed. Post treatment, mice showed significant improvements in cognition. Efficacy and safety features make Amytrap a promising candidate for treating or modulating AD.

Offering Summary


Company

:

Recombinant Technologies Inc.

Corporate Address

:

1090 Meriden Waterbury Tpke, Suite 1, Cheshire, CT 06410

Offering Minimum

:

$10,000.00

Offering Maximum

:

$1,070,000.00

Minimum Investment Amount

(per investor)

:

$200.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

10,000

Maximum Number of Shares Offered

:

1,070,000

Price per Share

:

$1.00

Pre-Money Valuation

:

$35,000,000.00











*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives*

Time-Based:

Friends and Family Early Birds

Invest within the first 48 hours and receive additional 20% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive additional 15% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive an additional 10% bonus shares.

Amount-Based:

$500+ | Tier 1

Invest $500 and receive 2% bonus shares. 

$1,000+ | Tier 2

Invest $1,000 and receive 5% bonus shares.

$2,500+ | Tier 3

Invest $2,500 and receive 7% bonus shares.

$5,000+ | Tier 4

Invest $5,000 and receive 10% bonus shares.

$10,000+ | Tier 5

Invest $10,000 and receive 15% bonus shares.

*All perks occur when the offering is completed.

Irregular Use of Proceeds

Example - The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$28,023.00 USD
$18,605.00 USD
Cash And Cash Equivalents
$123.00 USD
$205.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$140,219.00 USD
$149,919.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$492,479.00 USD
$562,257.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$118,775.00 USD
-$182,716.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Brand new Scientific Publication

10 days ago

https://www.heraldopenaccess.us/article_pdf/10/novel-api-coated-catheter-removes-amyloid-beta-from-plasma-of-patients-with-alzheimer-s-disease.pdf


We're excited to get this publication  out there and hope you'll join us on this journey. Invest today! Invest now and participate in our success. 



Notice of Funds Disbursement

24 days ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Recombinant Technologies has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Recombinant Technologies be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Press Releases for Recombinant Technologies

25 days ago

Recombinant has been talked about in various press releases (yahoo finance, marketwatch, Benzinga and seeking alpha).


We have press coverage from various publications this week! 

"Their patented technology was developed over ten years and has successfully improved memory in mice and proof of concept trials."

"Going beyond conventional modalities that only address the symptoms, Recombinant Technologies is focused on treating the root cause of Alzheimer's Disease delivering a huge improvement in the quality of life of those afflicted."


We're excited to get this technology out there and hope you'll join us on this journey. Invest today!


Notice of Funds Disbursement

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Recombinant Technologies has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Recombinant Technologies be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Founder-President

about 1 month ago

4g7rQNme.jpg

NIH (National Institutes of Health) has selected Recombinant technologies to receive a free TABA needs assessment!

RT is happy and proud of this selection. 
Technical and Business Assessment report will be useful to identify the tech and financial needs and help our company to benefit the most. The related work is fully funded by the National Institute on Aging. This is in addition to the 3M grant application that is pending with NIA. This selection is another milestone in the successful commercialization of the proposed devices to help patients with Alzheimer's Disease.

The team over at Vikriti Management Consulting, LLC (a CRO picked and paid by NIH to this assessment) will be taking a look at our company's technology and seeing how we can take it to the next level. 

This is just one of the steps that Recombinant Technologies is taking to get our name out there and in the hands of those who need it most. 


We would love if you join us in our journey as we revolutionize Alzheimer treatments. Invest Today!

Founder-President

about 2 months ago

Recombinant Technologies Inc (RT) is happy to announce that it has applied for a new $ 3 M grant (commercialization Readiness Pilot) from the National Institutes of Health (NIH) to expedite the commercialization of its amyloid capturing devices. It is a logic extension of the existing phase 2 grant from NIH. If funded, RT will perform additional research and development to optimize and fine-tune the two devices, obtain IDE (investigative device exemption) classification from FDA and get ready for commercialization. The proposed innovative devices may lead to achieving a novel treatment strategy that improves the lives of patients with AD.  RT is hopeful of a favorable outcome from the peer-review process. 

Founder-President

2 months ago

We are excited about the new partnership agreement between Recombinant Technologies and SA Capital Partners LLC  to raise additional capital to fund the device development to treat Alzheimer's. See news release below:

https://www.newswire.com/news/better-living-for-people-with-alzheimers-one-of-a-kind-device-and-21451926?_ga=2.108831554.1162561905.1629466685-444512394.1628694593

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}